GuidelineClinical pharmacology and therapeutics2011
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Abstract readPractice Guideline
In one paragraph
Guideline in Clinical pharmacology and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 14 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 14 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
204 citing papers in PubMed, 14 syntheses or guidelines pooled it.
- Interaction of CYP2C19 with the effect of clopidogrel in secondary prevention of major ischemic events: Systematic review and meta-analysis.International journal of stroke : official journal of the International Stroke Society · 2026Pooled it
- Efficacy and safety of dual antiplatelet therapy de-escalation in East Asian individuals following percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).British journal of clinical pharmacology · 2026Guideline
- Comparative effectiveness of pharmacogenomic-guided versus unguided antidepressant treatment in major depressive disorder: new insights from subgroup and cumulative meta-analyses.BMJ mental health · 2025Pooled it
- Comparative efficacy and safety of different durations of dual antiplatelet therapy in acute minor non-cardioembolic stroke: a systematic review and network meta-analysis.Journal of neurology · 2025Pooled it
- The association of CYP2C19 LoF alleles with adverse clinical outcomes in stroke patients taking clopidogrel: An updated meta-analysis.Clinical and translational science · 2024Pooled it
- Role of genetic polymorphisms in clopidogrel response variability: a systematic review.Open heart · 2023Pooled it
- Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.Clinical pharmacology and therapeutics · 2018Pooled it
- Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.Clinical pharmacology and therapeutics · 2017Guideline
- Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Annals of laboratory medicine · 2017Guideline
- Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials.British journal of clinical pharmacology · 2015Pooled it
- CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Pooled it
- Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Clinical pharmacology and therapeutics · 2013Guideline
- Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.Clinical pharmacology and therapeutics · 2013Guideline
- Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial.JAMA network open · 2025Trial
- Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.Scientific reports · 2021Trial
- Anti-Platelet Therapy in Mild Cerebral Infarction Patients on the Basis of CYP2C19 Metabolizer Status.Cell transplantation · 2019Trial
- Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial.Contemporary clinical trials · 2017Trial
- A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.The pharmacogenomics journal · 2016Trial
- CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.Journal of the American Heart Association · 2015Trial
144 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
S A ScottDepartment of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, USA.
K Sangkuhl
E E Gardner
C M Stein
J-S Hulot
J A Johnson
D M Roden
T E Klein
A R Shuldiner
Clinical Pharmacogenetics Implementation Consortium
Funding
PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2MPHARMACOGENOMICS OF ARRHYTHMIA THERAPYU01HL065962 · NHLBI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2001 to 2009
$24.8MTHE STANFORD PHARMACOGENETICS KNOWLEDGE BASEU01GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2009
$24.0MPharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7MPharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4MPharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6MMount Sinai Institutes for Clinical and Translational SciencesKL2TR000069 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SAMPSON, HUGH A · 2012 to 2014
$2.3MMount Sinai Institutes for Clinical and Translational SciencesKL2RR029885 · NCRR · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MURPHY, BARBARA T. · 2009 to 2011
$1.8MNCATS NIH HHS KL2 TR000069NCRR NIH HHS KL2 RR029885NHLBI NIH HHS U01 HL065962NHLBI NIH HHS U01 HL105198NHLBI NIH HHS U19 HL065962NHLBI NIH HHS U19 HL065962-10NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM61374NIGMS NIH HHS U01 GM061374NIGMS NIH HHS U01 GM074492PHS HHS U01 JL65962
Abstract
PubMed holds no abstract for this paper.
Indexed as
Acute Coronary SyndromeAllelesAngioplasty, Balloon, CoronaryAryl Hydrocarbon HydroxylasesClopidogrelCytochrome P-450 CYP2C19GenotypeHumansPharmacogeneticsPlatelet Aggregation InhibitorsTiclopidineAryl Hydrocarbon HydroxylasesClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsTiclopidine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.